CPSE:VIRO

Stock Analysis Report

Executive Summary

ViroGates A/S, a medical technology company, provides various products to measure soluble urokinase plasminogen activating receptor in blood.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Risks

  • ViroGates has significant price volatility in the past 3 months.
  • ViroGates is not covered by any analysts.

Share Price & News

How has ViroGates's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-5.7%

VIRO

0.3%

DK Medical Equipment

1.4%

DK Market


1 Year Return

-57.4%

VIRO

0.2%

DK Medical Equipment

7.0%

DK Market

VIRO underperformed the Medical Equipment industry which returned 1.5% over the past year.

VIRO underperformed the Market in Denmark which returned 7% over the past year.


Share holder returns

VIROIndustryMarket
7 Day-5.7%0.3%1.4%
30 Day-6.7%-4.5%0.3%
90 Day-22.1%4.0%2.9%
1 Year-57.4%-57.4%1.5%0.2%10.3%7.0%
3 Yearn/a67.4%59.2%34.8%23.6%
5 Yearn/a118.4%99.3%65.4%41.4%

Price Volatility Vs. Market

How volatile is ViroGates's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ViroGates undervalued based on future cash flows and its price relative to the stock market?

2x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for ViroGates to establish if it is available at moderate discount.

Unable to calculate intrinsic value for ViroGates to establish if it is available at substantial discount.


Price Based on Earnings

ViroGates is loss making, we can't compare its value to the DK Medical Equipment industry average.

ViroGates is loss making, we can't compare the value of its earnings to the Denmark market.


Price Based on Expected Growth

Unable to calculate PEG ratio for ViroGates, we can't assess if its growth is good value.


Price Based on Value of Assets

ViroGates is good value based on assets compared to the DK Medical Equipment industry average.


Next Steps

Future Growth

How is ViroGates expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ViroGates has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has ViroGates performed over the past 5 years?

-37.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

ViroGates does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare ViroGates's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare ViroGates's 1-year growth to the DK Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if ViroGates has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if ViroGates has efficiently used its assets last year compared to the DK Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if ViroGates improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is ViroGates's financial position?


Financial Position Analysis

ViroGates is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

ViroGates has no long term commitments.


Debt to Equity History and Analysis

ViroGates has no debt.

ViroGates currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Low level of unsold assets.

ViroGates has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

ViroGates has sufficient cash runway for 2.4 years based on current free cash flow.

ViroGates has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 51.8% each year.


Next Steps

Dividend

What is ViroGates's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate ViroGates's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate ViroGates's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as ViroGates has not reported any payouts.

Unable to verify if ViroGates's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as ViroGates has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of ViroGates's salary, the management and board of directors tenure and is there insider trading?

10.8yrs

Average management tenure


CEO

Jakob Knudsen (51yo)

8.4yrs

Tenure

0

Mr. Jakob Knudsen has been Director at ExpreS2ion Biotech Holding AB (publ) since April 19, 2017. Mr. Knudsen has been the Chief Executive Officer at ViroGates A/S since April 2011. Mr. Knudsen serves as a ...


Management Age and Tenure

10.8yrs

Average Tenure

56yo

Average Age

The average tenure for the ViroGates management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

4.6yrs

Average Tenure

58yo

Average Age

The tenure for the ViroGates board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Jakob Knudsen (51yo)

    Chief Executive Officer

    • Tenure: 8.4yrs
  • Jesper Eugen-Olsen (56yo)

    Co-Founder & Chief Scientific Officer

    • Tenure: 19.7yrs
  • Jørgen Thorball (57yo)

    Co-Founder & Director

    • Tenure: 18.7yrs
  • May Dyvelkov (59yo)

    Chief Financial Officer

    • Tenure: 10.8yrs
  • Thomas Krarup (56yo)

    Vice President of Global Sales & Marketing

    • Tenure: 1.5yrs

Board Members

  • Lars Krogsgaard (52yo)

    Director

    • Tenure: 3.4yrs
  • Jørgen Thorball (57yo)

    Co-Founder & Director

    • Tenure: 18.7yrs
  • Peter Aaby (75yo)

    Scientific Advisor

    • Tenure: 0yrs
  • Bernd Uder (62yo)

    Non-Executive Director

    • Tenure: 4.6yrs
  • Lars Kongsbak (58yo)

    Chairman of the Board

    • Tenure: 4.6yrs
  • Knut Borch-Johnsen

    Scientific Advisor

    • Tenure: 12.7yrs

Company Information

ViroGates A/S's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ViroGates A/S
  • Ticker: VIRO
  • Exchange: CPSE
  • Founded: 2000
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: ø105.808m
  • Shares outstanding: 3.03m
  • Website: https://www.virogates.com

Number of Employees


Location

  • ViroGates A/S
  • Blokken 45
  • Birkerød
  • Capital Region of Denmark
  • 3460
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VIROCPSE (OMX Nordic Exchange Copenhagen)YesShare CapitalDKDKKJun 2018

Biography

ViroGates A/S, a medical technology company, provides various products to measure soluble urokinase plasminogen activating receptor in blood. The company develops and markets suPARnostic, a blood test used ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 22:15
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.